IL6R and COVID-19: To this end, many labs screened for agents with the potential to be repurposed for COVID-19 patients and identified among others broad-spectrum antiviral agents (BSAAs) originally approved for Influenza or HIV and immunomodulatory and anti-inflammatory agents, such as the human IL-6 receptor (IL-6R) inhibitor tocilizumab as potential treatments for COVID-19 (Scavone et al., 2020; Singh et al., 2020).